Eli Lilly Announces GLP-1 Drug Efficacy and Raises Price Target
LLY Lilly(Eli) & Co
$1443.50 +1.14%
View chart & analysis → 
- 1Eli Lilly's experimental drug retatrutide showed a maximum 25% reduction in body weight and a 50% reduction in OA pain for high-dose users.
- 2Eli Lilly confirmed a maximum 44% reduction in sleep apnea among Foundayo users and plans to apply to the US FDA as a treatment by the end of this year.
- 3Jefferies raised its price target for Eli Lilly from $1,610 to $1,700.
So what's the key point?
Eli Lilly's new drug was effective in losing weight and reducing pain. Experts expect the stock to rise further and raised the target price to $1,700.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.